Unipharm Israel

What Unipharm Israel does

Unipharm Israel is a privately held, family-owned generic pharmaceutical company founded in 1973 by Zevulun (Zvika) Tomer. The company develops, manufactures, and distributes over 120 generic medications across therapeutic areas including central nervous system and mental health (depression, anxiety, schizophrenia, ADHD, bipolar disorder), cardiology (hypertension, heart failure, arrhythmias, hyperlipidemia, diabetes), urology, infectious diseases, sleep disorders, Alzheimer's disease, biosimilars, anesthesia, and ophthalmology. Manufacturing is conducted at the company's own plant near the Eliakim junction in Northern Israel, with management headquartered in Tel Aviv (Shvat Shimon 1). The firm is privately held with no parent company, subsidiaries, or disclosed institutional investors, and is currently led by the founder's sons, Gil Tomer and Ron Tomer, who serve as Co-CEOs.

The company's business model centers on producing bioequivalent generic versions of originator drugs that have come off-patent, competing on cost efficiency while meeting Israeli pharmaceutical quality and bioequivalence standards. Products are sold through Israel's four HMOs (Clalit, Maccabi, Meuhedet, Leumit), the national pharmacy network, and hospital/institutional channels, with reimbursement determined through the national health basket. This distribution structure gives Unipharm near-universal reach across the Israeli population — the company states it serves hundreds of thousands of citizens — although revenue remains undisclosed and pricing is set through centralized healthcare-system negotiations rather than direct-to-consumer channels. Marketing and physician engagement occur primarily through a published health guide, webinars, podcasts, social media, and professional-organization sponsorships.

Unipharm's market position was reinforced by a landmark 2021 Israeli Supreme Court ruling in its favor against Sanofi regarding the Plavix (Clopidogrel) patent, which established a global precedent expanding liability for patent fraud by originator drug companies and yielded Unipharm an NIS 2.6 million award. The case, which spanned more than a decade, was recognized with Generic Bulletin's "Patent Litigation of the Year" award. Founder Zevulun Tomer received the 2015 Industry Award from the Manufacturers Association in the presence of Israel's President, and Unipharm marked its 50th anniversary in November 2023. Operations remain active with no disclosed expansion beyond the Israeli market.

Name

Unipharm Israel

Legal name

אוניפארם בע"מ

Website

https://unipharm.co.il

Company type

Private

Founded year

1973

Operating status

Operating

Headcount range

11–50 employees

Short description

Unipharm Israel is a family-owned generic pharmaceutical company that manufactures over 120 medications across mental health, cardiology, urology, and other therapeutic areas, distributing them through Israel's four HMOs and pharmacy networks.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Generic drug manufacturing
• Cardiovascular medications
• Mental health medications
• Pharmaceutical products

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Sales: Unipharm generates revenue by developing, manufacturing, and selling generic pharmaceutical products. Generic drugs are sold at significantly lower prices than originator drugs after patent expiry, with the company competing on price and quality. The Israeli pharmaceutical market exceeds 6 billion shekels annually.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Unipharm Israel develops, manufactures, and distributes generic pharmaceutical products in Israel across more than 120 SKUs spanning mental health, cardiovascular, urology, infectious diseases, sleep, Alzheimer's, oncology biosimilars, ophthalmology, and bone health. Products are bioequivalent to originator drugs and sold at lower prices, distributed through Israeli HMOs, retail pharmacies, and hospitals at subsidized rates via the national health basket.

Product overview

Unipharm Israel is a generic pharmaceutical company that manufactures over 120 medications across multiple therapeutic areas. The company's product portfolio includes treatments for mental health conditions (depression, anxiety, ADHD, schizophrenia, bipolar disorder, autism, OCD, eating disorders), cardiovascular diseases (hypertension, heart failure, arrhythmias, blood clotting, hyperlipidemia, angina, heart rhythm disorders), urology (BPH, sexual function), sleep disorders, Alzheimer's disease and dementia, infectious diseases, digestive conditions (acid reflux), anesthesia, oncology (biosimilars), and respiratory diseases. The products include well-known brands such as MEMOX and MEMORIT for Alzheimer's treatment, ATOMIC for ADHD, SECTOR for cardiovascular health, NOCTURNO for sleep, and many others covering the full spectrum of therapeutic categories.

Differentiator

Problem solved

Functional benefit

Products and services

• MEMORIT 10 (ממוריט 10) Donepezil HCl 10mg oral tablet for the treatment of dementia (Alzheimer's disease) from mild to moderate severity. Generic bioequivalent version of an originator Alzheimer's therapy, dispensed in Israel via HMOs and pharmacies.
• MEMOX 20 (ממוקס 20) Memantine Hydrochloride 20mg tablet for the treatment of moderate to severe Alzheimer's disease. Generic alternative to the originator NMDA-receptor antagonist, dispensed in Israel via HMOs and pharmacies.
• MEMOX 10 (ממוקס 10) Memantine Hydrochloride 10mg tablet for the treatment of moderate to severe Alzheimer's disease. Lower-dose generic alternative within the MEMOX line, dispensed in Israel via HMOs and pharmacies.
• ATOMIC (18, 25, 40, 60, 80, 100mg) (אטומיק) Atomoxetine oral solution in multiple dosages for the treatment of ADHD (Attention Deficit Hyperactivity Disorder). Generic alternative to the originator non-stimulant ADHD therapy, available in Israel through HMOs and pharmacies.
• SECTOR (50, 100, 200mg) (סקטור) Cardiovascular medication indicated for heart health treatment, available in multiple dosages. Included in Israel's health basket with extended coverage in 2025 and distributed to hospitals and institutional healthcare providers as well as retail pharmacies.
• CARDILOC (1.25, 2.5, 5, 10mg) (קרדילוק) Cardiovascular medication in multiple dosages for heart health treatment. Generic alternative within Unipharm's broad cardiovascular portfolio.
• VENLA (37.5, 75mg) (וונלה) Medication for the treatment of depression and anxiety, available in two dosages. Generic alternative to the originator SNRI/SSRI-class therapy, dispensed in Israel via HMOs and pharmacies.
• NOCTURNO / NOCTURNO FORTE (נוקטורנו) Sleep medication for the treatment of insomnia, including a Forte (higher-strength) variant. Generic hypnotic dispensed in Israel via HMOs and pharmacies.
• EZECOR 10 (אזקור) Cardiovascular medication indicated for heart health treatment. Generic alternative within Unipharm's cardiovascular portfolio.
• TICATA (60, 90mg) (טיקאטה) Cardiovascular medication available in two dosages. Generic alternative within Unipharm's cardiovascular portfolio.
• RISPOND (1, 2, 3, 4mg) and RISPOND Oral Solution (ריספונד) Antipsychotic medication for the treatment of schizophrenia and related conditions, available as tablets across four dosages and as an oral solution. Generic alternative to the originator atypical antipsychotic.
• ZAPPA (5, 7.5, 10mg, ODT) (זאפה) Medication for depression and anxiety treatment, available as tablets and an orally disintegrating tablet (ODT) form. Generic alternative within Unipharm's CNS portfolio.
• TORVA (10, 20, 40, 80mg) (טורבה) Cardiovascular medication (statin-class) for heart health and lipid management, available in four dosages. Generic alternative within Unipharm's cardiovascular portfolio.
• STATOR (5, 10, 20, 40mg) (סטטור) Cardiovascular medication (statin-class) for heart health and lipid management, available in four dosages. Generic alternative within Unipharm's cardiovascular portfolio.
• LOTAN (12.5, 50, 100mg) and LOTAN PLUS (לוטן) Cardiovascular medication for heart health treatment, available in three dosages plus a combination (LOTAN PLUS) variant. Generic alternative for hypertension management.
• LERCAPRESS (10, 20mg) (לרקפרס) Cardiovascular combination medication for heart health treatment and hypertension. Generic alternative within Unipharm's cardiovascular portfolio.
• CANDOR (8, 16mg) and CANDOR PLUS (קנדור) Cardiovascular medication for heart health treatment, available in two dosages plus a combination variant. Generic alternative within Unipharm's cardiovascular portfolio.
• ARIPLY (5, 10, 15, 30mg) (אריפלי) Medication for the treatment of depression, available in four dosages. Generic alternative to the originator atypical antidepressant.
• PAXXET (20, 30mg) (פאקסט) Medication for the treatment of depression, available in two dosages. Generic SSRI-class alternative within Unipharm's CNS portfolio.
• MELODIL (25, 50mg) (מלודיל) Medication for the treatment of depression, available in two dosages. Generic tricyclic/tetracyclic antidepressant alternative.
• MARONIL 25 (מרוניל) Medication for the treatment of depression. Generic tricyclic antidepressant alternative.
• MIRO (30, 45mg) (מירו) Medication with sedating properties used for depression and sleep disorders. Generic antidepressant with sedative profile.
• TRAZODIL (50, 100mg) (טרזודיל) Medication for the treatment of depression. Generic trazodone-class antidepressant alternative.
• DEPREXAN (דפרקסאן) Medication for the treatment of depression. Generic antidepressant alternative within Unipharm's CNS portfolio.
• ESTO (10, 15, 20mg) (אסטו) Medication for depression and anxiety treatment, available in three dosages. Generic SSRI/SNRI-class alternative.
• TOREZ (10/10, 10/20, 10/40, 10/80mg) (טורז) Combination cardiovascular medication for heart health treatment. Fixed-dose combination generic within Unipharm's cardiovascular portfolio.
• DUPLEX (5/80, 5/160, 10/160mg) (דופלקס) Combination cardiovascular medication for heart health treatment. Fixed-dose combination generic for cardiovascular risk management.
• VECTOR (80, 160mg) and VECTOR PLUS (80/12.5, 160/12.5, 160/25mg) (וקטור) Cardiovascular medication for heart health treatment, available as monotherapy and fixed-dose combination (PLUS). Generic sartan/diuretic combination alternative.
• APIX (2.5, 5mg) (אפיקס) Cardiovascular anticoagulant medication for heart health treatment and stroke prevention. Generic apixaban-class alternative.
• ELTOP (25, 50mg) (אלטופ) Cardiovascular medication for heart health treatment. Generic beta-blocker or antihypertensive alternative.
• AMLODY (5, 10mg) (אמלודי) Cardiovascular medication for heart health treatment and hypertension. Generic amlodipine-class calcium channel blocker alternative.
• DIPPO 10 (דיפו) Cardiovascular medication for heart health treatment. Generic antihypertensive/antianginal alternative.
• LISSIN (30, 40, 50, 70mg) (ליסין) Cardiovascular medication for heart health treatment. Generic ACE-inhibitor or antihypertensive alternative.
• PRAVALIP (10, 20, 40mg) (פרבליפ) Cardiovascular medication (statin-class) for lipid management and heart health, available in three dosages. Generic pravastatin-class alternative.
• DRONCOR 400 (דרונקור) Cardiovascular medication for heart health treatment. Generic antiarrhythmic or related cardiovascular alternative.
• PROCOR 200 (פרוקור) Cardiovascular medication for heart health treatment. Generic antianginal or related cardiovascular alternative.
• GASTRO (10, 20, 40mg) (גאסטרו) Medication for digestive tract conditions including acid reflux, available in three dosages. Generic proton-pump inhibitor alternative.
• BACLOSAL (10, 25mg) (בקלוסל) Medication for muscle relaxation. Generic baclofen-class muscle relaxant alternative.
• ARMONIA and ARMONIA PLUS (ערמוניה) Medication for benign prostatic hyperplasia (BPH), available as monotherapy and combination (PLUS) variant. Generic urological alternative.
• CILARIL (1, 2.5, 5mg) and CILARIL PLUS (סילריל) Cardiovascular medication for heart health treatment, available as monotherapy and combination variant. Generic antihypertensive alternative.
• PRIZMA, PRIZMA FORTE and PRIZMA SOLUTION (פריזמה) Medication for heart health treatment, available in regular, Forte (higher-strength), and oral solution forms. Generic cardiovascular alternative.
• TARIM (50, 100mg) (תרים) Cardiovascular medication for heart health treatment. Generic antiplatelet or anticoagulant alternative.
• RECITAL (20, 40mg) (רסיטל) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• SERENADA (50, 100mg) (סרנדה) Medication for heart health treatment. Generic cardiovascular alternative.
• RIBONE (35, 150mg) (ריבון) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• PERICATE (פריקאט) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• KARIN (250, 500mg) (קארין) Antibiotic medication for infectious diseases, available in two dosages. Generic antibiotic alternative.
• ROXU (רוקסו) Medication for heart health treatment. Generic cardiovascular alternative.
• ROCURO (רוקורים) Medication used in anesthesia. Generic neuromuscular blocker alternative for anesthesia induction/maintenance.
• MAXIBONE 70 (מקסיבון) Medication for bone health and osteoporosis treatment. Generic bisphosphonate alternative.
• NEUBLOC 100 (ניאובלוק) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• PARKAL (פרקל) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• FLUDECATE (פלודקאט) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• SUGAMAX (סוגמקס) Medication for diabetes treatment. Generic antidiabetic alternative.
• SITAR PLUS (50/850, 50/1000mg) (סיטאר פלוס) Combination medication for diabetes treatment. Fixed-dose combination generic for diabetes management.
• PIRON (267, 801mg) (פירון) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• SORBON 10 (סורבון) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• PROTOCIDE (פרוטוציד) Medication for infectious diseases. Generic anti-infective alternative.
• ZODORM 10 (זודורם) Sleep medication for the treatment of insomnia. Generic hypnotic alternative.
• ZETTO (זטו) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• LEVO (לבו) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• CLOOD (קלוד) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• NORLIP (נורליפ) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• HERITY (הריטי) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• PEGIL (פגיל) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• SLIDER 20 (סליידר) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.
• PRIDE (100, 400mg) (פרייד) Cardiovascular medication for heart health treatment. Generic cardiovascular alternative.

Quantifiable outcome

• The Israeli pharmaceutical market exceeds 6 billion shekels annually, with generic drugs driving significant cost savings for the healthcare system.
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Seven partnerships are on record, tiered core and minor.

• Israel Manufacturers Association (התאחדות התעשיינים)coreStrategic or Co-development Partner · 1 January 2025Unipharm is an active member of the Israel Manufacturers Association, participating in CEO forums, industry events, and advocating for the generic pharmaceutical industry in Israel. CEO Forum visit to Unipharm documented in 2025.
• Civilian Command Center (החמ"ל האזרחי)minorStrategic or Co-development Partner · 1 January 2025Unipharm employees volunteered with the Civilian Command Center to help establish kindergartens and schools for evacuated children from Gaza border communities in Kibbutz Ruhama. The company also supported the restoration of Kibbutz Netiv HaOz.
• Israel Pharmacists Organization (ארגון הרוקחות)coreStrategic or Co-development Partner · 1 January 2024Unipharm sponsors the annual conference of the Israel Pharmacists Organization and supports their Best Lecture Competition. The company also worked with the organization on various professional events and initiatives. Additionally, Unipharm was a founding member of the organization.
• Yad SarahminorStrategic or Co-development Partner · 1 January 2024Unipharm supports Yad Sarah, a prominent Israeli healthcare charity, through donations and volunteer activities.
• KKL (Jewish National Fund — קק"ל)minorStrategic or Co-development Partner · 1 January 2024Unipharm employees volunteered with KKL to create new accessible hiking trails in the Nafha Stream area, contributing to community environmental infrastructure.
• Feuerstein Program (תכנית פוירשטיין)minorStrategic or Co-development Partner · 1 January 2024Unipharm provides financial support to the Feuerstein Program at Hebrew University, which helps students from disadvantaged backgrounds gain access to and integrate into academic programs.
• Brother and Sister to Israel (אחים ואחיות לישראל)minorStrategic or Co-development Partner · 1 January 2024Unipharm partnered with the Brothers and Sisters to Israel organization (operating the Civilian Command Center) for volunteer activities in southern Israel communities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Perrigo Company: Global manufacturer of generic prescription pharmaceuticals and consumer self-care products. Broad incumbent with comparable generic pharma manufacturing focus but at significantly larger scale and broader international footprint.
• Sandoz: Novartis's generics and biosimilars division, one of the world's largest generic pharmaceutical manufacturers. Comparable in generic-pharma manufacturing and biosimilars expansion strategy; operates as a much larger global incumbent.
• Teva Pharmaceutical Industries: Israel-founded global generic pharmaceutical leader with a broad generics and specialty portfolio. Comparable to Unipharm as the largest Israeli generic pharma incumbent but operates at vastly greater scale and international scope.
• Viatris: Global healthcare company formed from the Mylan-Upjohn combination with a substantial generic pharmaceuticals portfolio across therapeutic areas. Comparable generic-pharma product strategy and category breadth, but at global incumbent scale.

Direct peers

• Taro Pharmaceutical Industries: Israel-origin generic pharmaceutical manufacturer (now a Sun Pharma subsidiary) producing a wide range of generic prescription and OTC products. Directly comparable to Unipharm as another Israeli-rooted generic manufacturer with multi-category portfolios.
• Dexcel Pharma: Israeli-headquartered generic pharmaceutical company developing and manufacturing generic and specialty medicines. Closely comparable to Unipharm in geography, business model, and therapeutic breadth within the Israeli generics market.

Regional players

• CTS Chemical Industries: Israeli pharmaceutical manufacturer producing generic and specialty medicines for the domestic and selected international markets. Comparable as a domestic Israeli pharma manufacturer with overlapping generics and specialty focus.
• Kamada Ltd. Israeli specialty pharmaceutical company focused on specialty plasma-derived and biosimilar products. Comparable as an Israeli pharma peer with specialty/biosimilar manufacturing overlap, though positioned more in specialty than small-molecule generics.

Emerging players

• Aurobindo Pharma: India-based global generic pharmaceutical manufacturer with a broad portfolio across cardiology, CNS, and anti-infectives. Comparable in generic-pharma therapeutic mix and export-led generic strategy, though at larger scale.
• Dr. Reddy's Laboratories: India-headquartered global generic pharmaceutical company with a portfolio across cardiovascular, CNS, and gastroenterology. Comparable in therapeutic breadth and generic manufacturing focus, though at significantly larger global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/%D7%90%D7%95%D7%A0%D7%99%D7%A4%D7%90%D7%A8%D7%9D-%D7%A7%D7%A8%D7%99%D7%99%D7%A8%D7%94-UNP-210754212802928
• LinkedInlinkedin.com/company/unipharmil
• Instagraminstagram.com/unipharm_ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unipharm Israel